Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias

Journal of Clinical Oncology

Volumn 17, Issue 8, 1999, Pages 2454-2460

  Cheson, Bruce D ^a   Vena, Donald A ^a   Barrett, Jane ^a   Freidlin, Boris ^a  

^a EMMES CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; FLUDARABINE; NUCLEOSIDE ANALOG; PENTOSTATIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; BONE MARROW SUPPRESSION; BREAST CANCER; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; HAIRY CELL LEUKEMIA; HEAD AND NECK CANCER; HUMAN; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROSTATE CANCER; SARCOMA; SECOND CANCER; TESTIS CANCER;

EID: 0032812729     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.8.2454     Document Type: Article

References (51)

1. Keating MJ, O'Brien S, Kantarjian H, et al: Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 81:2878-2884, 1993
2. Keating MJ, O'Brien S, Lerner S, et al: Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92:1165-1171, 1998
3. Rai KR, Peterson B, Elias L, et al: A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia: A CALGB, SWOG, CTC/NCI-C and ECOG inter-group study. Blood 88:141a, 1996 (abstr 552)
4. Grever M, Kopecky K, Foucar MK, et al: A randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: An intergroup study. J Clin Oncol 13:974-982, 1995
5. Saven A, Burian C, Koziol JA, et al: Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 92:1918-1926, 1998
6. O'Brien S, Kantarjian H, Beran M, et al: Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 82:1695-1700, 1993
7. Urba WJ, Baseler MW, Kopp WC, et al: Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia. Blood 73:38-46, 1989
8. Steis RG, Urba WJ, Kopp WC, et al: Kinetics of recovery of CD4+ T cells in peripheral blood of deoxycoformycin-treated patients. J Natl Cancer Inst 83:1678-1679, 1991
9. Kraut EH, Neff JC, Bouroncle BA, et al: Immunosuppressive effects of pentostatin. J Clin Oncol 8:848-855, 1990
10. Seymour JF, Kurzrock R, Freireich EJ, et al: 2-Chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood 83:2906-2911, 1994
11. Seymour JF, Talpaz M, Kurzrock R: Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up. Leukemia 11:42-47, 1997
12. Betticher DC, Fey MF, von Rohr A, et al: High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias. Ann Oncol 5:57-64, 1994
13. Cheson BD: Immunologic and immunosuppressive complications of purine analog therapy. J Clin Oncol 13:2431-2448, 1995
14. Anaissie EJ, Kontoyiannis DP, O'Brien S, et al: Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 129:559-566, 1998
15. Manusow D, Weinerman BH: Subsequent neoplasia in chronic lymphocytic leukemia. JAMA 232:267-269, 1975
16. Greene MH, Hoover RN, Fraumeni JF Jr: Subsequent cancer in patients with chronic lymphocytic leukemia: A possible immunologic mechanism. J Natl Cancer Inst 61:337-340, 1978
17. Jacobs RH, Yokes EE, Golomb HM: Second malignancies in hairy cell leukemia. Cancer 56:1462-1467, 1985
18. Cheson BD, Vena D, Freidlin B, et al: The risk of secondary malignancies following purine analog therapy of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL). Proc Am Soc Clin Oncol 16:15a, 1997 (abstr 52)
19. Durrleman S, Grem JL, Cheson BD: 2′-deoxycoformycin after failure of alpha-interferon in hairy cell leukemia. Eur J Haematol 43:297-302, 1989
20. Sorensen JM, Vena D, Fallavollita A, et al: Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the Group C mechanism of the National Cancer Institute: Five-year follow-up report. J Clin Oncol 15:458-465, 1997
21. Cheson BD, Sorensen JM, Vena DA, et al: Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C Protocol mechanism of the National Cancer Institute: A report of 97 patients. J Clin Oncol 16:3007-3015, 1998
22. 2 tests. Biometrics 10:417-451, 1954
23. Fisher LD, Van Belle G: Biostatistics: A Methodology for the Health Sciences. New York, NY, J. Wiley, 1993
24. Bernstein L, Newton P, Ross RK: Epidemiology of hairy cell leukemia in Los Angeles County. Cancer Res 50:3605-3609, 1990
25. Berman E, Heller G, Kempin S, et al: Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a. Blood 75:839-845, 1990
26. Davis JW, Weiss NS, Armstrong BK: Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst 78:91-94, 1987
27. Diaz-Pavon JR, Pugh W, Cabanillas F: Simultaneous presentation of hairy cell leukemia and follicular small cleaved cell lymphoma in a patient with previous diagnosis of renal cell carcinoma. Hematol Oncol 13:63-67, 1995
28. Golomb HM, Ratain MJ, Mick R, et al: Interferon treatment for hairy cell leukemia: An update on a cohort of 69 patients treated from 1983-1986. Leukemia 6:1177-1180, 1992
29. Kurzrock R, Strom SS, Estey E, et al: Second cancer risk in hairy cell leukemia: Analysis of 350 patients. J Clin Oncol 15:1803-1810, 1997
30. Kwong YL, Liang R, Chiu E, et al: Hairy cell leukemia: Treatment results and association with secondary malignancy. Am J Hematol 48:291, 1995 (letter)
31. Molica S, Alberti A: Second neoplasms in chronic lymphocytic leukemia: Analysis of incidence as a function of the length of follow-up. Haematologica 74:481-485, 1989
32. Au WY, Klasa RJ, Gallagher R, et al: Second malignancies in patients with hairy cell leukemia in British Columbia: A 20-year experience. Blood 92:1160-1164, 1998
33. Van Scoy-Mosher MB, Bick M, Capostagno V, et al: A clinicopathologic analysis of chronic lymphocytic leukemia. Am J Hematol 10:9-18, 1981
34. Gabrail NY, Martin TW: Coexistence of essential thrombocythemia and chronic lymphocytic leukemia. Acta Hematol 85:31-33, 1991
35. Travis LB, Curtis RE, Hankey BF, et al: Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst 84:1422-1427, 1992
36. Stern N, Shemesh J, Ramot B: Chronic lymphatic leukemia terminating in acute myeloid leukemia: Review of the literature. Cancer 47:1849-1851, 1981
37. Choi H, Keller RH: Coexistence of chronic lymphocytic leukemia and Hodgkin's disease. Cancer 48:48-57, 1981
38. Schreiber ZA, Axelrod MR, Abebe LS: Coexistence of chronic myelogenous leukemia and chronic lymphocytic leukemia. Cancer 54:697-701, 1984
39. Eridani S, Parry H, Glass U, et al: Acute lymphoblastic leukemia supervening in a case of chronic lymphocytic leukemia after continuous 3-year treatment with chlorambucil. Cancer 54:397-399, 1984
40. Duchayne E, Delsol G, Kuhlein E, et al: Hairy cell transformation of a B-cell chronic lymphocytic leukemia: A morphological, cytochemical, phenotypic and molecular study. Leukemia 5:150-155, 1991
41. Catovsky D, Fooks J, Richards S: Prognostic factors in chronic lymphocytic leukaemia: The importance of age, sex and response to treatment in survival - A report from the MRC CLL 1 trial. Br J Haematol 72:141-149, 1989
42. Dighiero G, Maloum K, Desablens B, et al: Chlorambucil in indolent chronic lymphocytic leukemia: French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 338:1506-1514, 1998
43. Saltman DL, Ross JA, Banks RE, et al: Molecular evidence for a single clonal origin in biphenotypic concomitant chronic lymphocytic leukemia and multiple myeloma. Blood 74:2062-2065, 1989
44. Lopera GA, Alvarez OA, Lee M: Large cell lymphoma of the colon presenting as a second malignancy in a patient with hairy cell leukemia. J Clin Gastroenterol 21:259-260, 1995
45. Kampmeier P, Spielberger R, Dickstein J, et al: Increased incidence of second neoplasms in patients treated with interferon alpha 2b for hairy cell leukemia: A clinicopathologic assessment. Blood 83:2931-2938, 1994
46. Smith JW II, Longo DL, Urba WJ, et al: Prolonged, continuous treatment of hairy cell leukemia patients with recombinanat interferon-alpha 2a. Blood 78:1664-1671, 1991
47. Spielberger RT, Dickstein JI, Le Beau MM, et al: Acute myeloid leukemia following interferon-alfa therapy of hairy cell leukemia. Br J Haematol 83:519-520, 1993
48. Kraut EH, Grever MR, Bouroncle BA: Long-term follow-up of patients with hairy cell leukemia after treatment with 2′-deoxycoformycin. Blood 84:4061-4063, 1994
49. Flinn IW, Kopecky KJ, Foucar MK, et al: Long-term results in hairy cell leukemia (HCL) treated with pentostatin. Blood 90:578a, 1997 (abstr 2575)
50. Tallman MS, Hakimian D, Rademaker AW, et al: Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: Long-term follow-up of the Northwestern University experience. Blood 88:1954-1959, 1996
51. Hoffman MA, Janson D, Rose E, et al: Treatment of hairy-cell leukemia with cladribine: Response, toxicity, and long-term follow-up. J Clin Oncol 15:1138-1142, 1997